Posted on by ScienceFather
57 / 100
Powered by Rank Math SEO
SEO Score

Dr. Hamza Hashmi | Immunotherapy | Best Researcher Award

Assistant Professor at Memorial Sloan Kettering Cancer Center, United States.

Dr. Hamza Hashmi is a highly skilled oncologist with expertise in medical oncology, hematology, and cellular immunotherapy. He has a robust academic background, including a medical degree from King Edward Medical University in Lahore, Pakistan, followed by extensive postdoctoral training in internal medicine, hematology/oncology, and blood and marrow transplantation. Dr. Hashmi’s professional experience spans prestigious institutions such as Memorial Sloan Kettering Cancer Center and the University of Louisville. He is board-certified in internal medicine, medical oncology, and hematology, with active involvement in various professional organizations like the American Society of Hematology and the American Society of Clinical Oncology. Dr. Hashmi has received numerous honors and awards for his contributions to clinical trial enrollment and research. His research interests focus on advancing treatment modalities for hematologic malignancies, particularly through cellular immunotherapy and bone marrow transplantation. With a passion for education, Dr. Hashmi actively engages in teaching and mentoring activities, further enriching his contributions to the field of oncology.

Professional Profiles:

Education

Dr. Hamza Hashmi completed his medical education at King Edward Medical University in Pakistan, earning his M.B.B.S degree in 2011. He then underwent postdoctoral training, including roles as a Medical Officer in Internal Medicine and Hematology/Oncology in Lahore, Pakistan, followed by residencies and fellowships in Internal Medicine and Hematology Oncology in the United States. He specialized further in Blood and Marrow Transplantation and Cellular Immunotherapy at the H. Lee Moffitt Cancer and Research Center in Florida. Currently, he serves as an Assistant Professor at Memorial Sloan Kettering Cancer Center in New York, NY, demonstrating his commitment to advancing cancer care and research.

Professional Experience

Dr. Hamza Hashmi’s professional journey encompasses various roles in healthcare and academia. He began as a Medical Officer in Internal Medicine and Hematology/Oncology at Jamila Fareedy Hospital in Lahore, Pakistan. Later, he pursued residencies in Internal Medicine at Michigan State University and Hematology Oncology at the University of Louisville. Additionally, he underwent specialized training in Blood and Marrow Transplantation and Cellular Immunotherapy at the H. Lee Moffitt Cancer and Research Center in Florida. Currently, he holds an Assistant Professor position at Memorial Sloan Kettering Cancer Center in New York, NY, where he contributes to advancing cancer treatment and research. Throughout his career, Dr. Hashmi has demonstrated a commitment to providing high-quality patient care and contributing to the academic community through teaching and research.

Research Interest

Dr. Hamza Hashmi’s research interests primarily focus on hematologic malignancies, particularly multiple myeloma and lymphoma. He is particularly interested in exploring novel treatment modalities, including cellular immunotherapy and bone marrow transplantation, to improve outcomes for patients with these conditions. Additionally, Dr. Hashmi is interested in studying the molecular mechanisms underlying disease progression and treatment resistance in hematologic cancers. He is actively involved in clinical research aimed at identifying predictive biomarkers and developing targeted therapies tailored to individual patients. Overall, his research aims to advance our understanding of hematologic malignancies and develop innovative treatment strategies to improve patient outcomes.

Award and Honors

Dr. Hamza Hashmi has been recognized with prestigious awards for his outstanding contributions to oncology. Among these accolades is the Top Ten Publishers Club Award bestowed upon him by the Medical University of South Carolina in 2023. This award underscores Dr. Hashmi’s exceptional research output and academic contributions, positioning him as one of the top scholars in his field. Additionally, he has been honored with the Excellence in Clinical Trial Enrollment Award from the same institution in the same year. This recognition highlights Dr. Hashmi’s commitment to advancing cancer treatment through clinical research and his significant impact on patient care. These awards serve as testament to Dr. Hashmi’s dedication, expertise, and leadership in the field of oncology.

Research Skills

Dr. Hamza Hashmi possesses a diverse set of research skills honed throughout his academic and professional journey. With a strong foundation in medical oncology and hematology, he demonstrates proficiency in conducting clinical trials, analyzing data, and interpreting results. His expertise extends to cellular immunotherapy and bone marrow transplantation, areas where he has contributed significantly to the advancement of treatment modalities for hematologic malignancies. Dr. Hashmi is adept at literature review and synthesis, enabling him to stay abreast of the latest developments in oncology research. Furthermore, he excels in study design, protocol development, and patient recruitment, ensuring the successful implementation of research projects. His collaborative spirit and effective communication skills facilitate interdisciplinary collaboration and knowledge sharing, fostering innovation in cancer care. Overall, Dr. Hashmi’s research skills position him as a valuable asset in the pursuit of novel therapies and improved outcomes for cancer patients.

Publications

  1. Efficacy and safety of idecabtagene vicleucel in patients with relapsed–refractory multiple myeloma not meeting the KarMMa-1 trial eligibility criteria: A real-world multicentre study
    • Authors: Dima, D.; Rashid, A.; Davis, J.A.; Anwer, F.; Ahmed, N.
    • Journal: British Journal of Haematology
    • Year: 2024
  2. Safety and efficacy of eltrombopag in patients with post-CAR T cytopenias
    • Authors: Wesson, W.; Ahmed, N.; Rashid, A.; Abdallah, A.-O.; Hashmi, H.
    • Journal: European Journal of Haematology
    • Year: 2024
  3. Safety and Efficacy of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma: A Real-World Experience
    • Authors: Dima, D.; Davis, J.A.; Ahmed, N.; Abdallah, A.-O.; Hashmi, H.
    • Journal: Transplantation and Cellular Therapy
    • Year: 2024
  4. Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
    • Authors: Davis, J.A.; Dima, D.; Ahmed, N.; Abdallah, A.-O.; Hashmi, H.
    • Journal: Transplantation and Cellular Therapy
    • Year: 2024
  5. Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment
    • Authors: Sidana, S.; Peres, L.C.; Hashmi, H.; Patel, K.K.; Hansen, D.K.
    • Journal: Haematologica
    • Year: 2024
  6. Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
    • Authors: Oluwole, O.O.; Dholaria, B.; Knight, T.E.; Anderson, L.D.; Hamadani, M.
    • Journal: Transplantation and Cellular Therapy
    • Year: 2024
  7. Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy
    • Authors: Peres, L.C.; Oswald, L.B.; Dillard, C.M.; Hansen, D.K.; Patel, K.
    • Journal: Blood Advances
    • Year: 2024
  8. Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma
    • Authors: Dima, D.; Mansour, R.; Davis, J.A.; Abdallah, A.-O.; Hashmi, H.
    • Journal: European Journal of Haematology
    • Year: 2024
  9. Impact of age, obesity, and renal impairment on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma
    • Authors: Gaffney, K.J.; Bakos, J.K.; Velayati, A.; Hess, B.T.; Hashmi, H.
    • Journal: Journal of Oncology Pharmacy Practice
    • Year: 2024
  10. Impact of race and ethnicity on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma
    • Authors: Davis, J.A.; Thurlapati, A.; Weeda, E.; Green, K.; Hashmi, H.
    • Journal: Annals of Hematology
    • Year: 2024
Hamza Hashmi | Immunotherapy | Best Researcher Award

You May Also Like